Report Highlights
The global market for cardiac biomarkers is estimated to increase from $13.4 billion in 2022 to reach $23.8 billion by 2027, at a compound annual growth rate (CAGR) of 12.2% from 2022 through 2027.
Report Includes
- 66 data tables and 36 additional tables
- An up-to-date overview and analysis of the global markets for cardiac biomarkers technologies
- Analyses of the global market trends, with historic revenue data for 2019-2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
- Estimation of the actual market size and revenue forecast for cardiac biomarkers market in USD million terms, and corresponding market share analysis based on the type of biomarker, instrument category, and region
- Identification of the viable technology drivers and barriers through a holistic review of various platform technologies in cardiac biomarker measurement and their notable advancements
- Complete understanding of the leading cardiac markers and their value in terms of diagnostic testing, screening, prognostic monitoring, pharmacogenomic testing, and theranostics, while also appreciating these elements from their basic principles to their applications
- Discussion of feasible market opportunities via identification of high-growth applications in different cardiac marker diagnostic testing areas, with a focus on the biggest and fastest-expanding markets for diseases
- Emphasis on global industry development through an in-depth analysis of the major world markets for cardiac marker diagnostic testing, including forecasts for growth
- Latest information on the leading companies engaged in research and development (R&D) and products in the cardiac marker diagnostic reagent pipeline with SWOT analyses
- Review of the patents and patent applications on cardiac biomarkers and deep dive of recent global and region-specific patent publications related to cardiac biomarkers
- Insight into the company competitive landscape and company value share analysis for the leading suppliers of cardiac biomarkers
- Profile descriptions of the major global players, including Abbott Laboratories, Beckman Coulter (subsidiary of Danaher Corp.), bioMérieux S.A., PerkinElmer Inc., Roche Diagnostics, Siemens Healthineers, and Thermo Fisher Scientific Inc.
Report Scope
The scope of this report is:
- Identify viable technology drivers through a comprehensive look at various platform technologies for cardiac marker segments of the diagnostic testing market.
- Obtain a complete understanding of the leading cardiac markers and their value in terms of diagnostic testing, screening, prognostic monitoring, pharmacogenomic testing and theragnostic, while also gaining an appreciation these elements from their basic principles to their applications.
- Discover feasible market opportunities via the identification of high-growth applications in different cardiac marker diagnostic testing areas, with a focus on the biggest and fastest-expanding markets for diseases.
- Focus on global industry development through an in-depth analysis of the major world markets for cardiac marker diagnostic testing, including forecasts for growth.
- Present market figures for the current value of the cardiac biomarkers market, projections and growth rates. These are developed from the most recently available information from the global diagnostics industry.
By purchasing this study, the reader will gain:
- An improved understanding of the current state and future of the most exciting cardiac biomarker market segments.
- The latest information on the leading companies engaged in research and development (R&D) and products in the cardiac marker diagnostic reagent pipeline.
- Knowledge of the cardiac diagnostic testing market as an area of growth, research and investment.
This analysis covers the following categories of the cardiac biomarker segments:
- Acute Myocardial Infarction (AMI).
- Heart failure.
- Brain natriuretic peptide (BNP).
- Myoglobin.
- Homocysteine (Hcy).
- C-reactive protein (CRP).
- Pulmonary embolism (PE) D-dimer test.
- Low-density lipoproteins (LDL) and high-density lipoproteins (HDL).
- Stroke.
- Creatine kinase-myocardial band (CK-MB) and cardiac enzymes.
- Albumin.
- Cardiac markers are used in clinical decisions.
- Cardiac markers in renal failure.
- Troponins in non-ischemic heart disease.
- Cardiac panels.
- POC cardiac markers.
Analyses include charts and graphs measuring product growth and trends within the marketplace. In addition, a discussion of research on various illnesses provides the reader with a deeper understanding of the possibilities for future treatment and avenues for possible R&D budgets. Company-specific information, including sales figures, product pipeline status and R&D trends, is provided throughout the report. In addition, the study:
- Assesses cardiac marker diagnostic testing market drivers and bottlenecks from the perspective of the medical and scientific communities.
- Discusses the potential benefits of the cardiac marker diagnostic testing market for various sectors of the medical and scientific community.
- Establishes the current total market size and future growth of the cardiac marker diagnostic testing market and analyzes the current size and growth of individual segments.
- Provides current and forecasted market shares by company.
- Discusses profit and business opportunities by diagnostic testing segment.
- Provides strategic recommendations for near-term business opportunities.
- Assesses current commercial uses of the cardiac biomarker market.
Report Synopsis
| Report Metrics | Details | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Base year considered | 2021 | ||||||||||||||||||||||||||||||
| Forecast period considered | 2022-2027 | ||||||||||||||||||||||||||||||
| Base year market size | $11.9 billion | ||||||||||||||||||||||||||||||
| Market size forecast | $23.8 billion | ||||||||||||||||||||||||||||||
| Growth rate | CAGR of 12.2% for the forecast period of 2022-2027 | ||||||||||||||||||||||||||||||
| Units considered | $ Millions | ||||||||||||||||||||||||||||||
| Segments covered | By Type of Biomarker, Instrument Category, and Region | ||||||||||||||||||||||||||||||
| Regions covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) | ||||||||||||||||||||||||||||||
| Countries covered | U.S., Canada, France, Germany, Italy, Spain, U.K., Japan, China, India, South Korea, Australia, Rest of Europe, Rest of APAC | ||||||||||||||||||||||||||||||
| Key Market Drivers |
|
||||||||||||||||||||||||||||||
| Companies studied |
|
||||||||||||||||||||||||||||||
Frequently Asked Questions (FAQs)
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
- Global Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market (BIO269A)
- Global DNA Forensics Market (BIO266A)
- Industry 4.0 Technologies: Global Market Through 2030 (MFG042B)
- Global Blood Platelet Market (BIO268A)
- Smart Medical Devices: Global Markets (MDS066B)
Related Reports
2024 Diagnostics Research Review
The Biology industry is a multi-billion-dollar industry whose outlook is supposed to rise in the coming years. This report provides a sampling of the types of quantitative market information, analysis and guidance that has been aiding business decision making since the inception of BCC Research in 1971.
Biomarkers: Technologies and Global Markets
The global market for biomarkers was valued at $63.7 billion in 2023. This market is expected to grow from $70.5 billion in 2024 to $130.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 13.1% from 2024 through 2029.
Point-of-Care Diagnostics: Technologies and Global Markets
The global market for point-of-care diagnostics was valued at $36.9 billion in 2023. It is expected to grow from $40.6 billion in 2024 to $65.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.2% from 2024 through 2029.
Companion Diagnostics: Technologies and Markets
The global market for companion diagnostics is estimated to increase from $7.6 billion in 2023 to reach $15.4 billion by 2028, at a compound annual growth rate (CAGR) of 15.2% from 2023 through 2028.
Track the Latest Global Tariff Developments
In today's fast-paced global economy, tariffs are no longer static—they are dynamic levers shaped by geopolitical realignments, supply chain vulnerabilities, inflationary pressures, and sustainability-driven trade reforms. As governments worldwide recalibrate their trade strategies, businesses are left to navigate a maze of shifting rules, rising costs, and regulatory uncertainty.
Our analysis empowers you with real-time updates and in-depth expert analysis on all facets of global tariff activity. From new trade agreements and sanctions to abrupt tariff hikes and retaliatory duties, we monitor developments across borders, sectors, and industries—so you don't have to.
Whether it's the ongoing U.S.–China trade dynamics, the evolving EU Carbon Border Adjustment Mechanism (CBAM), or the emerging policies in India, ASEAN, and Latin America, we provide full-spectrum coverage. We also track multilateral trade negotiations, World Trade Organization (WTO) rulings, and sector-specific duty structures—ensuring you are always ahead of global trade shifts.
With our analysis, you can stay informed, identify risks, and confidently respond to tariff changes—no matter where you operate.
Ready to see what tariff means for your business?
Consult with our experts or request your custom Tariff Impact Brife today
Stay Informed, Stay Competitive
In today's interconnected and unpredictable global economy, staying ahead of tariff shifts is not just important—it's essential. BCC Research provides decision-makers with trusted, research-driven insights that turn uncertainty into opportunity.
Our in-depth market analysis and trade intelligence help you decode how tariff changes impact your specific sector—manufacturing, healthcare, technology, agriculture, or energy. We break down complex data into actionable knowledge through comprehensive reports, expert commentaries, and sector-focused forecasts.
Our analysis includes:
- Thorough breakdowns of current and proposed tariff policies and how they affect regional and global trade flows.
- Sector-specific implications, helping you understand the strategic impact on sourcing, pricing, and competitiveness.
- Forward-looking insights to support risk management, planning, and response strategies for evolving trade conditions.
With BCC Research, you gain more than just information—you gain clarity and confidence to make well-informed decisions in a volatile trade environment.
Don't let tariffs catch you off guard—let our insights guide your strategy.
Recent Reports
Global Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market
The global market for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics is expected to grow from $33.3 billion in 2025 and is projected to reach $52.6 billion by the end of 2030, at a compound annual growth rate (CAGR) of 9.6% during the forecast period of 2025 to 2030.
Global DNA Forensics Market
The global market for DNA forensics is projected to grow from an estimated $3.3 billion in 2025 to $4.7 billion by the end of 2030, at a compound annual growth rate (CAGR) of 7.7% from 2025 to 2030.
Global Blood Platelet Market
The global market for blood platelets is expected to grow from $3.2 billion in 2025 and is projected to reach $4 billion by the end of 2030, at a compound annual growth rate (CAGR) of 4.6% during the forecast period of 2025 to 2030.
Digital Biomarkers: Global Markets
The global market for digital biomarkers is estimated to grow from $5 billion in 2025 to $18.8 billion by the end of 2030, at a compound annual growth rate (CAGR) of 30.4% from 2025 through 2030.
Whole Genome Sequencing: Global Markets
The global market for whole genome sequencing is expected to grow from $3 billion in 2025 and forecast to reach $6.1 billion by the end of 2030, at a compound annual growth rate (CAGR) of 15.1% from 2025 to 2030.
Top Trending Reports
Sensors: Technologies and Global Markets
The global market for sensors was valued at $195.1 billion in 2024 and is estimated to increase from $212.5 billion in 2025 to reach $323.3 billion by 2030, at a compound annual growth rate (CAGR) of 8.7% from 2025 through 2030.
Global Cell Line and Membrane Market
The global market for cell lines and membranes was valued at $5.7 billion in 2024 and is estimated to increase from $6.3 billion in 2025 to reach $11.4 billion by 2030, at a compound annual growth rate (CAGR) of 12.5% from 2025 through 2030.
Water and Wastewater Treatment Technologies: Global Markets
The global market for water and wastewater treatment technologies is expected to grow from $350.7 billion in 2025 and is projected to reach $591.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 11.0% during the forecast period of 2025 to 2030.
Global Edge AI Market
The global market for edge AI was valued at $8.7 billion in 2024 and is estimated to increase from $11.8 billion in 2025 to reach $56.8 billion by 2030, at a compound annual growth rate (CAGR) of 36.9% from 2025 through 2030.
Global Biochip Markets: Microarrays and Lab-on-a-Chip
The global market for biochip was valued at $16.1 billion in 2024 and is estimated to reach $27.8 billion by 2029, at a compound annual growth rate (CAGR) of 11.6% from 2024 through 2029.
Report Highlights
The global market for cardiac biomarker will grow from $6.3 billion in 2017 to $9.9 billion by 2022, at a compound annual growth rate (CAGR) of 9.5% for the period of 2017-2022
Report Includes
- 64 data table and 40 additional tables
- An overview of the global market for cardiac biomarkers and related technologies
- Analyses of global market trends, with data from 2016 to 2017, and projections of compound annual growth rates (CAGRs) through 2022
- Classification of cardiac biomarkers by cerebrovascular, congestive, coronary, hypertensive, and peripheral arterial disease
- Background and clinical values of cardiac biomarkers, including B-type natriuretic peptide (BNP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), C-reactive protein (CRP), choline, creatine kinase MB (CK-MB), D-dimer, glial fibrillary acidic protein (GFAP), heart fatty acid binding protein (H-FABP), ischemia-modified albumin (IMA), myeloperoxidase (MPO), myoglobin, soluble fragment CD40 ligand (sCD40L), and troponin I (cTnI)/troponin T (cTnT)
- Examination of the technology regarding diagnostic methods, instrumentation, newly issued patents, and new patent applications
- Coverage of clinical guidelines and government regulations
- Comprehensive company profiles of major Players in the Market including Abbott Laboratories, Biomérieux S.A., Bio-Rad Laboratories Inc, Life Diagnostics Inc., Meridian Life Science Inc. Randox Laboratories Ltd., Roche, Sanyo Chemical Industries Ltd., Siemens Ag, and Thermo Fisher Scientific Inc.
Report Highlights
The global cardiac biomarkers market has grown to $4.9 billion in 2015 from $4.4 billion in 2014. The market is expected to grow at a five-year compound annual growth rate (CAGR) of 12.4% from 2015 to 2020, increasing to over $8.8 billion in 2020.
Report Includes
- An overview of the global market for cardiac biomarkers and related technologies.
- Analyses of global market trends, with data from 2014, 2015, and projections of CAGRs through 2020.
- Classification of cardiac biomarkers by cerebrovascular, congestive, coronary, hypertensive, and peripheral arterial disease.
- Background and clinical values of cardiac biomarkers, including B-type natriuretic peptide (BNP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), C-reactive protein (CRP), choline, creatine kinase MB (CK-MB), D-dimer, glial fibrillary acidic protein (GFAP), heart fatty acid binding protein (H-FABP), ischemia-modified albumin (IMA), myeloperoxidase (MPO), myoglobin, soluble fragment CD40 ligand (sCD40L), and troponin I (cTnI)/troponin T (cTnT).
- Examination of the technology covering diagnostic methods, instrumentation, newly issued patents, and new patent applications.
- Clinical guidelines and government regulations.
- Profiles of major players in the industry.
Report Highlights
The global market for in vitro diagnostic tests for cardiac biomarkers was estimated at $3.1 billion in 2012 and nearly $4 billion in 2013. This market is predicted to reach $7.2 billion by 2018, at a compound annual growth rate (CAGR) of 12.8% over the five-year period from 2013 to 2018.
Report Includes
- An overview of the global market for biomarkers for cardiovascular disease (CVD) and related technologies.
- Analyses of global market trends, with data from 2012, estimates for 2013, and projections of CAGRs for the period 2013 to 2018.
- Classification of CVD by cerebrovascular, congestive, coronary, hypertensive, and peripheral arterial disease.
- Background and clinical values of cardiac biomarkers, including B-type natriuretic peptide (BNP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), C-reactive protein (CRP), choline, creatine kinase MB (CK-MB), D-dimer, glial fibrillary acidic protein (GFAP), heart fatty acid binding protein (H-FABP), ischemia-modified albumin (IMA), myeloperoxidase (MPO), myoglobin, soluble fragment CD40 ligand (sCD40L), and troponin I (cTnI)/troponin T (cTnT).
- Examination of the technology covering diagnostic methods, instrumentation, newly issued patents, and new patent applications.
- Clinical guidelines and government regulations.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More